All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry

People with human immunodeficiency virus (HIV) (PWH) with 4-drug class resistance (4DR) had a higher risk of death than non-4DR PWH, primarily due to lower CD4 cell counts. The priority for this vulnerable population is achieving virological control to enable immune recovery.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2025-07-30
DOI
https://doi.org/10.1093/cid/ciaf421
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry

Federica Malerba, Daniela Valenti, Silvia Lamonica, Maurizio Zazzi et al.
Clinical Infectious Diseases
HIV/AIDS drug development and treatment
article

All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry

Federica Malerba, Daniela Valenti, Silvia Lamonica, Maurizio Zazzi, Antonio Di Biagio, Camilla Muccini, Daniele Armenia, Riccardo Lolatto, Marcello Tavio, Marcello Feasi, Tiziana Formenti, Spinello Antinori, Maria Mazzitelli, Massimo Puoti, Valentina Da Ros, Andrea Galli, Tommaso Clemente, Elisa Garlassi, Roberto Gulminetti, Tiziana Mulas, Rachele Pincino, Loredana Sarmati, Davide Minisci, Maria Teresa Demitri, Laura Comi, Marcello Trizzino, Chiara Fornabaio, Diletta Laccabue, Massimiliano Fabbiani, Stefano Nardi, Francesca Pennati, Elio Manzillo, Silvia Fantino, Nicolò Capra, Andrea Calcagno, Adriana Cervo, Matteo Bassetti, Emanuele Focà, Benedetto Maurizio Celesia, Vincenzo Olivadese, Romina Corsini, Flavia Balena, Pierluigi Viale, Antonio Sarà, Leonardo Calza, Daniela Francisci, Giancarlo Orofino, Paolo Fusco, Elisa Fronti, Elisabetta Schiaroli, Giuseppe Vittorio De Socio, Filippo Lagi, Stefano Rusconi, Claudia Suardi, Elisabetta Carini, Emanuele Pontali, Vincenzo Spagnuolo, Susanna Giachè, Antonio Cascio, Federico D’Amico, Carmen Giarratana, Sabrina Bagaglio, Marisa Fusto, Francesco Castelli, Alessio Bellucci, Ilaria Rancan, Francesca Panza, Barbara Menzaghi, Mario Tumbarello, Marta Fiscon, Margherita Torti, Pierluigi Francesco Salvo, Carlo Torti, Giulia Marchetti, Layla Pagnucco, Maddalena Farinazzo, Roberta Gagliardini, Seble Tekle Kiros, Annalisa Saracino, Federica Carli, Cristina Mussini, Teresa Santantonio, Sergio Lo Caputo, Ornella Schioppa, Riccardo Riccardi, Bruno Cacopardo, Silvia Cretella, Cristina Moioli, Francesco Saladini, Rebecka Papaioannu Borjesson, A Narducci, Michele Salvatore Paternò Raddusa, Giovanni Di Perri, Angelo Pan, Cecilia Costa, Alessandro Bartoloni, Vincenzo Malagnino, Paola Brambilla, F Lo Schiavo, Filippo Ducci, Amedeo Lanzardo, Elisa Mirabelli, Maria Mercedes Santoro, Girolamo Piromalli, Giovanni Cenderello, Sergio Ferrara, Paola Corsi, Sabrina Blanchi, Simona Di Giambenedetto, Chiara Fornabaio, Alessandra Mataloni Paggi, Anna Maria Cattelan, Lidia Gazzola, Fabiana Trionfo Fineo
article en

Abstract

People with human immunodeficiency virus (HIV) (PWH) with 4-drug class resistance (4DR) had a higher risk of death than non-4DR PWH, primarily due to lower CD4 cell counts. The priority for this vulnerable population is achieving virological control to enable immune recovery.

Clinical Infectious DiseasesVol. 81(5)
AOL (United States) (US), Vita-Salute San Raffaele University (IT), University of Milan (IT), Agostino Gemelli University Polyclinic (IT), Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT), Ospedale San Paolo (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Azienda USL di Bologna (IT), Torino e-district (IT), IRCCS Ospedale San Raffaele (IT), ASST Fatebenefratelli Sacco (IT), Istituti Ospitalieri di Cremona (IT), Azienda Socio Sanitaria Territoriale di Cremona
Gilead Sciences, ViiV Healthcare, Mylan, Cilag
Good health and well-being
Openalex Percentile: Top 77%
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.